TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05015855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-PC PrEP
Description: All participating providers will be provided standard education around PrEP and HIV prevention, but half of the providers will be randomized to also partner with a nurse practitioner who will provide additional consultation to patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: OBGYN-PrEP
Description: OBGYN-PrEP is based on PC4PrEP (R01MH107297) that has four steps: announce the policy that PrEP counseling is the responsibility of OBGYN providers to address the purview paradox; train providers to manage patients on PrEP; use a screening tool to identify women appropriate for PrEP; and implementation coaching to monitor and encourage PrEP counseling
Study: NCT04730635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo capsule QD, orally for Days 1-56.
Study: NCT06563466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The experimental intervention PEGASUS
Description: See arm description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: See arm description
Study: NCT05734443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-treadmill trip training
Description: Participants practice volitional and reactive stepping responses that mimic those needed when recovering balance after tripping.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill trip training
Description: Sudden treadmill changes in speed (from standing) induce trip-like losses of balance, after which participants take steps to recover balance and establish a stable gait pattern. This is repeated over a range of speeds to both provide training variability and to individualize training to each participant's capability.
Study: NCT04017819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-C-SNAT4
Description: Radiotracer- Dose 10 mCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-C-SNAT4
Description: Radiotracer- Dose 10 mCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-C-SNAT4
Description: Radiotracer- Dose 10 mCi

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography (PET)/Computed tomography (CT) Scan
Description: Positron emission tomography (PET)/Computed tomography (CT) Scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/Computed tomography (CT) Scan
Description: Positron emission tomography (PET)/Computed tomography (CT) Scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/Computed tomography (CT) Scan
Description: Positron emission tomography (PET)/Computed tomography (CT) Scan
Study: NCT06255002

Intervention type: BIOLOGICAL
Intervention: Fibrinogen concentration by the qLabs®FIB Monitoring system
Description: A drop of blood (\~15 μL) is taken from the blood sample for the complete haemostasis assessment (prothrombin level, activated partial thromboplastin time, fibrinogen). This assessment is part of the usual management of severe postpartum haemorrhage. It is carried out urgently in the hospital's medical biology laboratory at the start of treatment (T1) and during or at the end of treatment of the haemorrhage (T2). This drop of blood will allow the measurement of the fibrinogen concentration by the qLabs®FIB Monitoring system for the study at these two times.
Study: NCT06651268

Intervention type: DRUG
Group type: OTHER
Intervention: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
Description: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
Description: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
Study: NCT05779241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYN-005
Description: Risperidone long-acting oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYN-005
Description: Risperidone long-acting oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone immediate release (IR) oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone immediate release (IR) oral tablets
Study: NCT05312749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercises
Description: progressive relaxation exercises
Study: NCT05148650

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard laboratory coagulation tests and rotational thromboelastometry measurements
Description: Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard laboratory coagulation tests and rotational thromboelastometry measurements
Description: Blood for coagulation tests (thromboelastometry, aPTT, PT, INR, fibrinogen concentration, D dimers) and blood morphology was collected just before and immediately after the fluid infusion. With the use of a vacuum system, 20 ml of blood was collected through an IV cannula. The first 5 ml of blood were disposed of due to the possible interference with vascular stasis and fluid infusion on the measurements results.~Functional tests of coagulation were analysed through ROTEM. ROTEM coagulation analysis was carried out using a ROTEM delta analyzer (Tem Innovations GmbH, Munich, Germany), and assays were allowed to run for 60 minutes. Assays were run immediately after blood sampling to minimize a preanalytical error. Three ROTEM assays were run simultaneously, INTEM, EXTEM, and FIBTEM.
Study: NCT05606211

Intervention type: OTHER
Intervention: No intervention
Description: Observational, no intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational, no intervention
Study: NCT04930276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet intervention
Description: Professionals will guide participants to have a standard diet and require them to monitor blood glucose by themselves.
Study: NCT04752774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Powder and solvent for solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder and solvent for solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Powder and solvent for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dysport
Description: Powder for solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dysport
Description: Powder for solution for injection
Study: NCT06373107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity gait training
Description: Participants will practice walking that is vigorous enough to keep their heart rate over a certain level during their physical therapy sessions. During the sessions, participants will walk and step vigorously enough to keep the heart rate between 60-80% of their maximum heart rate. Maintaining this heart rate during exercise helps to improve heart health and walking, which can affect people after a stroke.
Study: NCT06136741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT06353178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Connect Program
Description: Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cancer Connect Program
Description: Online group peer program where participants learn evidence based skills for managing stressors and emotions related to their cancer experience.
Study: NCT06117774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT06166303

Intervention type: DIAGNOSTIC_TEST
Intervention: sFlt-1/PGIF
Description: Index of sFlt-1/PGIF

Intervention type: DIAGNOSTIC_TEST
Intervention: sFlt-1/PGIF
Description: Index of sFlt-1/PGIF
Study: NCT05236725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Blood Pressure Cuff
Description: specialized, Bluetooth enabled BP monitoring cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure (BP) monitoring smart phone app, BabyScripts™
Description: app that works with the monitoring cuff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructions
Description: Verbal and written instructions to conduct BP checks at home
Study: NCT05924620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: finerenone
Description: Patients with PA divided into Intervention group need to take finerenone for 60 days (20mg qd).
Study: NCT05466162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue mobilization
Description: Soft tissue massage therapy includes Madenci hand massage technique initiate with 30-second (sec) effleurage, followed by 60- sec friction, 30-sec petrissage, 30-sec shaking, and ends with 30-sec effleurage. It takes totally of 3 min Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~. Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint and nerve mobilization
Description: Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint and nerve mobilization
Description: Passive mobilizations of the wrist : radio-carpal joint in flexion and extension, maintained hand in traction. (30 oscillations, 5 sets and 30 secs interval between each step)~Inter-carpal horizontal flexion and extension. (30 oscillations, 5 sets and 30 secs interval between each step)~Nerve Mobilization treatment( Slider technique) followed by Shoulder will be in depression, abduction on gleno-humeral joint and rotated externally, forearm will be in a supination, elbow flexion and wrist, elbow extension and wrist, thumb, and finger flexion Treatment sessions: 3set, 10 reps, with hold for 10 secs.
Study: NCT04869644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting
Description: Goal setting: set or agree on a goal defined in terms of behavior to be achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Planning
Description: Action planning: prompt detailed planning of performance of behavior (must include a setting \[walking to the mailbox\], frequency, duration, and intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of behavior
Description: Self-Monitoring of behavior: establish a method for person to monitor and record their number of steps based on their Fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Practice/Rehearsal
Description: Behavioral rehearsal: prompt practice or rehearsal of walking one or more times in a context when the performance may not be necessary, in order to increase habit and skill.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Formation
Description: Prompt rehearsal \& repetition of walking 2,000 steps or more in the same context repeatedly so that the context elicits the behavior.
Study: NCT06499155

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of periacryl in gingival recession closure procedures
Description: Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of periacryl in gingival recession closure procedures
Description: Unlike the traditional procedure, periacryl tissue adhesive will be used in both the recipient and donor areas.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of sutures in gingival recession closure procedures
Description: Both recipient and donor areas will be closed with traditional suturing techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of sutures in gingival recession closure procedures
Description: Both recipient and donor areas will be closed with traditional suturing techniques.
Study: NCT06531109

Intervention type: DRUG
Intervention: Ritlecitinib
Description: As provided in the real world practice.
Study: NCT05619211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint-Intensity Interval Training with Telecoaching
Description: Maximal intensity exercises that use the arms.
Study: NCT06434610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B013
Description: B013: The subjects will receive IV dose of B013 600 mg on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel: 80 mg/m\^2 is administered weekly on Day 1, 8, 15 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: The subjects will receive IV dose of placebo matched to B013 on Day 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Study: NCT06008756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: Enlicitide Decanoate 20 mg tablet taken by mouth.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matched to enlicitide decanoate taken by mouth.
Study: NCT05735730

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: The study intervention consists of a blood draw for genetic analysis.
Study: NCT04551729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle advice for liberal fluid intake
Description: Lifestyle advice for liberal fluid intake for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle advice for liberal fluid intake
Description: Lifestyle advice for liberal fluid intake for 3 months
Study: NCT05744921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered subcutaneously (SC) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered subcutaneously (SC) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC Q4W
Study: NCT04337710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: Mom's milk or donor milk at 60-80 ml/kg/day after randomization within the first 24 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Enteral Nutrition
Description: Mom's milk or donor milk at 20-30 ml/kg/day after randomization within the first 24 hours.
Study: NCT05857553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfer
Description: Unconditional monthly transfer of $500 to household

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Direct Cash Transfer
Description: No intervention
Study: NCT05035953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol
Description: Edaravone Dexborneol 37.5 mg (containing Edaravone 30 mg and Dexborneol 7.5 mg), BID, 14 days, addition to thrombolysis
Study: NCT06306729

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, Magnetic Resonance Imaging
Description: Computed Tomography, Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography, Magnetic Resonance Imaging
Description: Computed Tomography, Magnetic Resonance Imaging
Study: NCT06658795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) on the Left DLPFC
Description: The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. For stimulating the lDLPFC, the positive electrode was placed at position F3, and the negative electrode was placed in the right supraorbital area/FP2 (e.g., Dubreuil-Vall et al., 2021, Biol Psychiatry: CNNI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) on the right VLPFC
Description: The tDCS parameters were set to a current of 2mA for a single session lasting 20 minutes. Based on the EEG 10-20 international system, the positive electrode for stimulating the rVLPFC was placed at position F6, while the negative electrode was placed in the left supraorbital area/FP1 (e.g., He et al., 2020, Psychol Med)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation group
Description: The electrode positions were randomized to match those of the rVLPFC or lDLPFC groups, but the stimulation only lasted for the first 30 seconds.
Study: NCT06097832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NXC-201 CAR-T
Description: NXC-201 (formerly HBI0101) CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The NXC-201 CAR-T is provided fresh without cryopreservation.
Study: NCT05265312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: START diabetes prevention clinical pathway
Description: The diabetes prevention clinical pathway will focus on the following steps:~1. Screen/test - testing of eligible patients for prediabetes/diabetes~2. Education - PCPs will be encouraged to take an online learning module and in-person group training on prediabetes management and patients with prediabetes will receive a handout about prediabetes prior to their upcoming PCP visit~3. Action - PCPs will use a shared decision-making guide and treatment algorithm to discuss options with patients at their visit~4. Referral - patients may be referred to DPPs and/or medical nutrition therapy (MNT)~5. Treat - patients will be scheduled for a follow-up visit within 3-9 months with their PCP or care team to continue addressing prediabetes.
Study: NCT06662071

Intervention type: OTHER
Intervention: Organoid culture
Description: Organoid culture of tumor tissue obtained during patient surgery

Intervention type: OTHER
Intervention: Organoid culture
Description: Organoid culture of tumor tissue obtained during patient surgery